© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Nicole Lamanna, MD, and Nirav N. Shah, MD, discuss the use of BTK inhibitors as targeted therapy for chronic lymphocytic leukemia and recent advancements.
January 28th 2022
Nicole Lamanna, MD, and Nirav N. Shah, MD, discuss the chronic lymphocytic leukemia treatment (CLL) landscape, including risk factors and treatment options.
Dr Lamanna introduces covalent BTK inhibitors and their use in patients with CLL
February 4th 2022
Dr Lamanna explains the challenges associated with BTK inhibitors.
Nicole Lamanna, MD, continues her discussion on BTK inhibitor challenges.
February 11th 2022
Dr Shah introduces non-covalent BTK inhibitors and clinical findings from their use in the CLL landscape.
Dr Shah explains the clinical implications of using BTK inhibitors for CLL treatment.
February 18th 2022
Dr Lamanna expands on BTK clinical implications within CLL therapy.
Two experts discuss the use of BTK inhibitors in the treatment of other B-cell malignancies.
Nicole Lamanna, MD, and Nirav N. Shah, MD, conclude with their thoughts on the future of BTK inhibitors in CLL.